Country: Canada
Language: English
Source: Health Canada
DIHYDROERGOTAMINE MESYLATE
STERIMAX INC
N02CA01
DIHYDROERGOTAMINE
1MG
LIQUID
DIHYDROERGOTAMINE MESYLATE 1MG
INTRAMUSCULAR
1ML
Prescription
SYMPATHOLYTIC (ADRENERGIC BLOCKING) AGENTS
Active ingredient group (AIG) number: 0108813001; AHFS:
APPROVED
1997-08-01
1 PRESCRIBING INFORMATION PR DIHYDROERGOTAMINE (DHE) (dihydroergotamine mesylate injection USP) Solution, 1 mg / mL for Subcutaneous, Intramuscular or Intravenous Use USP Migraine Therapy SteriMax Inc. 2770 Portland Drive Oakville ON L6H 6R4 Date of Revision: October 1, 2019 2 PRESCRIBING INFORMATION PR DIHYDROERGOTAMINE (DHE) (dihydroergotamine mesylate injection USP) Solution, 1 mg / mL THERAPEUTIC CLASSIFICATION Migraine Therapy ACTIONS AND CLINICAL PHARMACOLOGY Dihydroergotamine displays agonist activity at the 5-HT 1Da and 5-HT 1Dß receptors, which, by reducing 5-HT neuronal function and/or contracting elements of the cranial vasculature and/or suppressing neurogenic inflammation, is believed to underlie its anti- migraine efficacy. It also displays affinity for the 5-HT 1A and 5-HT 1C receptors and antagonistic activity at the 5-HT 2 subtype. Dihydroergotamine displays blocking actions at alpha adrenoreceptors, with a direct stimulating effect on the smooth muscle of peripheral blood vessels. Its tonic effect on capacitance vessels (veins) is particularly pronounced, compared to its effects on resistance vessels (arterioles). Dihydroergotamine differs from ergotamine by being more potent with respect to its adrenergic blocking actions and less potent with respect to its capacity to produce arterial vasoconstriction, but it maintains a marked venoconstrictor effect. Dihydroergotamine reduces the incidence and degree of nausea, photophobia, and phonophobia. Dihydroergotamine is 93% bound to plasma proteins. Its apparent volume of distribution is about 30 L/kg. The total body clearance is about 1.5 L/min., reflecting mainly the 3 hepatic clearance. Elimination from the plasma is biphasic with an a-phase of 1.5 hours and a ß-phase of 15 hours. The major route of excretion is via the bile in the faeces. Urinary excretion of parent substance and metabolites amounts to about 10% after intravenous administration. Pharmacokinetic interactions have been reported in patients treated orally with other ergot alkaloids Read the complete document